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Abstract Connective tissue growth factor (CTGF), also
known as CCN2, is implicated in fibrosis through both
extracellular matrix (ECM) induction and inhibition of
ECM degradation. The role of CTGF in inflammation in
cardiomyocytes is unknown. In some mesenchymal cell
systems, CTGF mediates effects through TGF-β or tyrosine
kinase cell surface receptor, TrkA, signalling. In this study,
cellular mechanisms by which CTGF regulates pathways
involved in fibrosis and inflammation were explored.
Murine H9c2 cardiomyocytes were treated with recombi-
nant human (rh)CTGF and ECM formation gene expres-
sion: fibronectin, collagen type -I and -III and ECM
degradation genes: TIMP-1, TIMP-2 and PAI-1 were found
to be induced. CTGF treatment also increased pro-
inflammatory cytokines TNF-α, IL-6, MCP-1 and IL-8.
CTGF upregulated TGF-β1 mRNA and rapidly induced
phosphorylation of TrkA. The CTGF-induced pro-fibrotic
and pro-inflammatory effects were blocked by anti-TGF-β
neutralizing antibody and Alk 5 inhibitor (SB431542). A
specific blocker of TrkA activation, k252a, also abrogated
CTGF-induced effects on fibrosis and gene expresison of
MCP-1 and IL-8, but not TNF-α or IL-6. Collectively, this
data implicates CTGF in effects on pro-fibrotic genes and
pro-inflammatory genes via TGF-β pathway signalling and
partly through TrkA.
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Cardiomyocytes
Introduction
The predominant cell type in the heart, the cardiomyocyte,
is implicated in the pathologies of both fibrosis and
inflammation that can occur in the myocardium. For
example, the heart disease of diabetic cardiomyopathy
(DCM) (Fang et al. 2004) involves inflammatory
(Westermann et al. 2007; Wang & Cai 2006) and fibrotic
changes (Samuel et al. 2008) including effects mediated by
cardiomyocytes (Wang and Cai 2006; Wang et al. 2009).
Pro-fibrotic factors such as collagen-I, collagen-III and
fibronectin (Wang et al. 2009) and pro-inflammatory
cytokines such as interleukin-6 (IL-6) and tumour necrosis
factor-α (TNF-α), are increased in DCM (Westermann et
al. 2006). However the cellular mechanisms mediating
these changes are still not completely understood.
Also known as CCN2, the protein CTGF is considered
to be a mediator involved in fibrotic processes (Leask and
Abraham 2004) and it stimulates fibroblast growth and
ECM protein up-regulation in vitro and in vivo. CTGF
over-production has been proposed to play a major role in
pathways that lead to fibrosis in many organs (Frazier et al.
1996; Igarashi et al. 1993). Increased CTGF expression has
been described in diabetes including DCM (Wang et al.
2009; Way et al. 2002) and post-myocardial infarct (Dean
et al. 2005). CTGF has been shown to induce the inhibitors
of matrix metalloproteinases known as TIMPS, leading to
ECM accumulation in renal cells (McLennan et al. 2004).
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changes in cardiomyocytes remain minimally explored and
whether CTGF has any effects on inflammatory processes
in cardiomyocytes has not been reported.
In some mesenchymal cell systems, CTGF appears to
function by modulating bioactivity of other cytokines,
especially TGF-β (Abreu et al. 2002), indicating that
TGF-β protein is required for CTGF to exert its effect. In
contrast, in a renal based cell system, CTGF was reported
to function through the cell surface receptor, TrkA (tyrosine
kinase A), leading to activation of TGF-β inducible early
gene (TIEG), and TGF-β pathway signalling (Wahab et al.
2005). Thus in some cells both TrkA and TGF-β based
pathways have been implicated in CTGF effects.
With this background, the aims of this study in
cardiomyocytes were to test whether (a) CTGF regulates
pro-fibrotic and pro-inflammatory gene expression in
cardiomyocytes; (b) whether CTGF effects on fibrosis and
inflammation are TGF-β dependent; and/or through the cell
surface receptor TrkA in cardiomyocytes.
Materials and methods
Reagents
Recombinant human CTGF (rhCTGF) protein was pro-
duced using an adenoviral expression system, purified with
heparin-Sepharose affinity chromatography using HiTrap
Heparin HP columns (Amersham Biosciences, Piscataway,
NJ, USA) and quantified as previously described (Tan et al.
2008). A chemical inhibitor of TrkA activity, k252a,
purchased from Merck-Calbiochem, Melbourne, Australia
was prepared by dissolving in DMSO, with final DMSO
concentration in cell culture at 0.001%. Pan anti-TGF-β
neutralizing antibody was purchased from R&D systems
Inc (Minneapolis, USA) and Alk 5 inhibitor (SB 431542)
was purchased from Tocris Cookson Inc, Ellisville, Mis-
souri USA. Rat nerve growth factor (NGF) was purchased
from Sigma (St. Louis, Mo, USA). Antibodies for detection
of phospho-TrkA (Tyr490) and total TrkA were purchased
from Cell Signaling Technology, Danvers, MA, USA. The
α-tubulin antibody was purchased from Abcam Inc
(Cambridge, MA, USA).
Cell treatment
The well studied murine H9c2 cells derived from embryonic
ratheart myocardiumwerepurchasedfromATCC(Rockville,
M D ,U S A ) .C e l l sw e r ec u l t u r e di nD M E Mc o n t a i n i n gn o r m a l
5.5 mM glucose, 4.4 mM L-glutamine and 1.7 g/L bicarbon-
ate supplemented with 10% FBS, 50 U/ml of penicillin and
50 μg/ml of streptomycin. Each experiment was performed at
least three times independently with in each experiment,
triplicate wells of treatments.
Cells were grown in 6-well plates until ∼80% confluent
and then treated with reagents in serum-free fresh DMEM
media containing 0.1% BSA (Sigma, St Louis, MO, USA).
Cells were harvested at 24 h. Treatments included control
media, rhCTGF, k252a (TrkA chemical blocker), Pan anti-
TGF-β neutralizing antibody, SB 431542 (Alk 5 inhibitor)
and combination treatments of rhCTGF with k252a or
TGF-β antibody or SB 431542. In the case of k252a or SB
431542 the highest relevant concentration of DMSO was
used as control. DMSO alone was shown in preliminary
studies not to affect mRNA levels measured compared with
no DMSO addition (not shown).
Total RNA isolation and analysis by quantitative real-time
PCR
TotalRNAofeachcelltreatmentwasisolatedfromcellsusing
the RNeasy Mini kit (Qiagen). RNA amount was quantitated
spectrophometrically (Bio-Rad Laboratories Inc, CA, USA),
and the purity was determined from the A260/A280 ratio (at or
above 1.80, to 2.00). RNA was then reverse transcribed to
cDNA using Random Hexamer Primer (Invitrogen, CA,
USA) and SuperScript™ III Reverse Transcriptase (Invitro-
gen). The resulting cDNAwas analyzed by quantitative real-
time PCR using Rotor Gene 6000 (Corbett Research), using
SYBR green as fluorescence dye, as described previously
(Tan et al. 2008). Relative quantitation of mRNA expression
in the gene of interest was calculated using the comparative
threshold cycle number for each sample. In each case, the
gene of interest expression level was normalized to 18s
ribosomal RNA and related to the relevant control, as
previously described (Twigg et al. 2002; Twigg et al.
2001). Four groups of genes were measured (a) CTGF and
TGF-β1; (b) ECM genes: fibronectin, collagen type - I and -
III; (c) ECM protease inhibitors: tissue inhibitors of matrix
metalloproteinases, TIMP-1, TIMP-2, TIMP-3, TIMP-4 and
plasminogen activator inhibitor 1, PAI-1; and (d) pro-
inflammatory cytokines: TNF-α, MCP-1, IL-6 and IL-8.
The primer sequences used are listed in Table 1.
TNF-α detection in conditioned media
A commercial ELISA assay (R&D Systems, Minneapolis,
MN, USA) was used to measure the protein level of rat
TNF-α in conditioned media after CTGF treatment (0–
500 ng/mL), as per the manufacturer’s instructions.
Preparation of cell lysates for protein quantitation
Cells were washed with cold Phosphate Buffer Saline
(PBS), then 150 μl of cold RIPA lysis buffer with a
16 X. Wang et al.complete protease inhibitor cocktail at concentration rec-
ommended by the manufacturer (Roche Diagnostics, NSW,
Australia) was added to each well. Plates were left on ice
for 20 min, and lysates were collected after centrifugation at
10,000 g for 10 min at 4°C. Total protein concentration was
measured using the DC Protein Assay (Bio-Rad Laborato-
ries, Richmond, CA) and was used for sample loading for
SDS-PAGE.
Western immunoblot analysis
Cell lysate samples were loaded at 30 µg of total protein
per lane and separated on a 4% to 12% gradient SDS-PAGE
gel (Invitrogen, Melbourne, Australia). Proteins were
electrotransferred onto nitrocellulose, and membranes were
blocked with 5% nonfat dry milk/TBS with 0.1% (Vol/Vol)
Tween 20 for 1 h, followed by incubation in either anti-
phospho-TrkA (1:150), or anti-total TrkA (1:300) as
previously described (Wang et al. 2009). Briefly, after
incubation of membranes with the appropriate horseradish
peroxidase (HRP)-labeled secondary antibody (1:10,000,
Vector Laboratories) for 1 h at 21°C. Immunoreactive
protein bands were then detected using enhanced chemilu-
minescence (Amersham Biosciences, Piscataway, NJ,
USA). In each case, after stripping of nitrocellulose
membranes with stripping buffer, anti-α-tubulin (1:5000)
at 4°C overnight followed by the relevant secondary
antibody then enhanced chemiluminescence as described
above, was used to detect α-tubulin as the loading control.
Statistical analysis
Results are expressed as the mean value ± SD. All
numerical data were derived from three or more indepen-
dent experiments. Differences between groups were
assessed using one way ANOVA, or Student’s two-tailed
paired t test where only two groups were to be compared, as
indicated in the text. P<0.05 was considered statistically
significant.
Results
CTGF increased ECM accumulation and degradation genes
as well as inflammatory genes markers in cardiomyocytes
To assess whether CTGF can induce fibrosis and inflam-
mation gene expression in cardiomycytes, H9c2 cells were
treated with 500 ng/ml of CTGF for 24 h in serum free
conditions. Gene expression of ECM formation and
degradation markers and pro-inflammatory cytokines were
measured by RT-qPCR. CTGF treatment increased the
ECM formation genes of fibronectin (FN), Collagen type-I
(Col-I) and Collagen type -III (Col-III) to 160%, 143% and
149% compared with no CTGF addition 100% control for
each gene respectively (Fig. 1a). Then, mRNA levels of
matrix protease inhibitors TIMP-1 to TIMP-4 and PAI-1
were also measured. TIMP-1 and TIMP-2 and PAI-1 were
up-regulated by rhCTGF while TIMP-3 and TIMP-4 were
not changed (Fig. 1b). Furthermore, elevated mRNA levels
of TNF-α, IL-6, IL-8 and MCP-1 occurred by the same
treatment (Fig. 1c). The protein concentration of TNF-α in
condition media measured using rat TNF-α ELISA kit was
induced ∼2-fold induction by 24 h of CTGF treatment
(Fig. 1d).
Effects of TGF-β and TrkA signalling on CTGF gene
expression
CTGF is able to induce its own gene expression in
mesenchymal derived cells as previously described
(McLennan et al. 2004). To study if CTGF mRNA is
Genes Forward sequences Reverse sequences
CTGF 5′-gaggaaaacattaagaagggcaaa 5′-cggcacaggtcttgatga
FN 5′-gctgctgggacttccacgt 5′-tctgttccgggaggtgca
Collagen I 5′-gcgaaggcaacagtcgattc 5′-cccaagttccggtgtgactc
Collagen III 5′-cagctggccttcctcagactt 5′-gctgtttttgcagtggtatgtaatg
PAI-1 5′-ggtcatggaacagaatg 5′-ctgagactagaatggctg
TIMP1 5′-aatttgcacatcactgcc 5′-gtgatcgctctggtagc
TIMP2 5′-atttatctacaccggcccc 5′-caagaaccatcacttctcttg
TNF-α 5′-agtcttccagctggagaagg 5′-gccactacttcagcatctcg
MCP-1 5′-tctcttcctccaccactatgca 5′-ggctgagacagcacgtggat
IL-6 5′-gcccttcaggaacagctatga 5′-tgtcaacaacaacatcagtcccaaga
IL-8 5′-aaacccgcctgtgttcga 5′-tcagtctggtctgggattcgt
TGF-β15 ′-aggtcacccgcgtgctaat 5′-tcaaccactgccgcacaact
18s 5′-cggctaccacatccaaggaa 5′-gctggaattaccgcggct
Table 1 Primer sequences used
in qRT-PCR to assess mRNA
levels of respective genes
Regulation of pro-inflammatory and pro-fibrotic factors 17regulated via TGF-β pathways or through TrkA signalling,
to potentially augment fibrotic and inflammatory markers in
cardiomyocytes, blockers of TGF-β (anti-TGF-β antibody),
TGF-β receptor-I (Alk5) and TrkA activity (K252a) were
studied, each pre-treated on H9c2 cells for 1 h before
rhCTGF (0–500 ng/mL) was added. Induced CTGF mRNA
by rhCTGF treatment was fully inhibited to baseline by
pan-specific anti-TGF-β antibody (Fig. 2a) and by the Alk5
blocker SB431542 (Fig. 2b). An inhibitory effect was also
seen by blocking TrkA activity, using k252a at 100 nM and
200 nM (Fig. 2c). In each case, the basal steady state CTGF
mRNA level in the absence of added rhCTGF was also
significantly inhibited by each reagent, consistently implicat-
ing TGF-β and TrkA signalling in CTGF mRNA regulation.
TGF-βdependent effects of rhCTGF on fibrotic
and inflammatory gene expression
To further test if CTGF regulation of fibrotic and
inflammatory factors is through TGF-β pathways, anti-
TGF-β Ab and the Alk 5 inhibitor (SB431542) each alone
or combined with rhCTGF were applied to the H9c2 cells.
Table 2 lists the gene expression of ECM formation,
degradation and pro-inflammatory genes examined under
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Fig. 1 CTGF increases fibrotic
and inflammatory gene expres-
sion in H9c2 cardiomyocytes.
Cells were treated with CTGF
500 ng/ml in serum free media
with 0.1% BSA at 80% conflu-
ence, and mRNA expression
was measured by real-time RT-
PCR after 24 h. A, mRNA
expression of ECM formation
genes of FN, Col-I and Col-III.
B, mRNA expression of ECM
degradation genes TIMP-1 to
TIMP-4 and PAI-1. C, Gene
expression of inflammatory
markers of TNF-α, IL-6, IL-
8 and MCP-1. D, TNF-α con-
centration was quantitated by
ELISA in conditional media
collected 24 h after CTGF
treatment(500 ng/ml and
1000 ng/ml). Data is mean±SD.
* P<0.05 vs respective control
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Fig. 2 Effects of TGF-β and TrkA signalling on CTGF gene
expression in H9c2 cells. Cells were pre-treated with anti-TGF-β
neutralizing antibody at 5 μg/ml (TGF-β Ab), Alk-5 inhibitor
(SB431542) at 5 μM , or TrkA blocker (k252a) at 100 nM and
200 nM alone in some wells for 1 h followed by addition of
unconditioned media alone or CTGF 500 ng/ml in serum free media
with 0.1% BSA for 24 h. CTGF mRNA levels were measured by qRT-
PCR and are shown compared with control at 100%. A, CTGF mRNA
measurement by treatment with CTGF, anti-TGF-β Ab or combina-
tions of CTGF with anti-TGF-β Ab. B, Alk 5 inhibitor. C, k252a
effects on CTGF gene expression. Data shown as mean±SD. * P<0.05
vs respective control.
#P<0.05,
##P<0.01,
###P<0.001 vs CTGF
treatment
18 X. Wang et al.treatments of rhCTGF (500 ng/ml), anti-TGF-β Ab (5 μg/
ml) and a mixture of CTGF and anti-TGF-β Ab. FN, Col-I
and Col-III mRNA species induced by CTGF were fully
blocked by anti-TGF-β Ab compared with the no treatment
control respectively. Similar results were found for PAI-1,
TIMP-1, TIMP-2 mRNA levels. For inflammatory genes,
CTGF induction compared with control was inhibited using
the anti-TGF-β Ab as a blocker of endogenous TGF-β.
The effect of Alk 5 inhibitor (SB431542) was then
studied. The induction of most gene expression in the three
groups by rhCTGF was prevented by the Alk 5 inhibitor
(Table 3). PAI-1 mRNA showed a very strong inhibitory
effect with both Alk 5 inhibitor alone in the basal state and
in combination treatment with rhCTGF, suggesting that
PAI-1 mRNA is strongly dependent on the TGF-β
signalling pathway (Table 3).
In combination the data in Tables 2 and 3 indicate that
CTGF regulation of fibrotic and inflammatory genes is
TGF-β and TGF-β pathway dependent.
CTGF signalling through TrkA to induce TGF-β1
To confirm whether CTGF signals through TrkA, the H9c2
cells were treated with rhCTGF for up to 120 min and cell
lysate was isolated and probed by Western immunoblot.
Phosphorylation of TrkA was induced by added CTGF
from 15 min (Fig. 3a). In contrast total TrkA was
unchanged. These findings are consistent with those that
we recently reported, in a less detailed time course
(McLennan et al. 2004). As TGF-β1 gene expression is
induced by TGF-β pathway activation, subsequent studies
focussed on TGF-β1 mRNA as a read out at 24 h. These
experiments showed that rhCTGF induced TGF-β1 mRNA
levels, which was blocked by the TrkA activity inhibitor,
k252a and also by anti-TGF-β antibody (Fig. 3b). Collec-
Table 2 Anti-TGF-β neutralising antibody effects on CTGF regulat-
ed fibrotic and inflammatory gene expression in H9c2 cardiomyocytes
mRNA
species
detected
Cell Treatments
CTGF
(500ng/ml)
TGF-β Ab
(5μg/ml)
CTGF
+TGF-β
Ab
ECM
formation
genes
FN 159±15.2* 105±18.9 97±14.7#
Col I 152±4.28* 85±14.9 94±7.3#
Col III 149±10.2 94±13.2 94±8.8#
ECM
remodeling
genes
PAI-1 189±16.7* 87±11.2 102±6.8#
TIMP-1 145±8.3* 68±7.4** 60±9.7#
TIMP-2 149±11.4* 93±15.6 108±7.6#
Pro-
inflammatory
genes
TNF-α 151±20.9* 107±28.6 125±23.5
IL-6 147±8.5 71±11.5* 110±16.5#
IL-8 156±9.2* 90±16.1 71±14.5#
MCP-1 169±10.2* 80±10.8 73±19.5#
Data is expressed as % of control (at 100%). * P<0.05, **P<0.01 vs
control; # P<0.05 vs CTGF treatment
Table 3 Effects of TGF-β type I receptor (Alk-5) blocker on CTGF
regulated fibrotic and inflammatory gene expression in H9c2
cardiomyocytes
mRNA
species
detected
Cell Treatments
CTGF
(500ng/ml)
Alk 5
inhibitor
(SB431542)
(5μM)
CTGF+Alk 5
inhibitor
SB431542
(5μM)
ECM
formation
genes
FN 177±29.6* 110±62.5 51±19.7#
Col I 151±22.3* 103±35.8 128±26.9#
Col III 147±12.9 131±45.8 87±23.6#
ECM
remodelling
genes
PAI-1 203±34.1* 4±1.2*** 8±1.8# ##
TIMP-1 203±21.5* 45.8±25.3* 49±41.0#
TIMP-2 197±29.0* 121±18.8 153±24.3#
Pro-
inflammatory
genes
TNF-α 198±22.9* 74.9±8.3* 78±43
IL-6 167±30.5 41.2±8.0** 87±31.6
IL-8 155±19.8* 175±46.8 137±58.9
MCP-1 175±33.8 256±32.1* 99±13.9#
Data is expressed as % of control (at 100%). *P<0.05, **P<0.01,
***P<0.001 vs control; #P<0.05, ###P<0.001 vs CTGF treatment
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Fig. 3 CTGF phosphorylation of TrkA and upregulation of TGF-β1
mRNA. A, Addition of rhCTGF to H9c2 cells induced rapid
phosphorylation of TrkA but did not increase total TrkA. B, rhCTGF
application to cells induced TGF-β1 mRNA, which was inhibited by
anti-TGF-β1 antibody or k252a. Data is mean±SD. *, P<0.05, vs
control.
#P<0.05,
##P<0.01 vs CTGF treatment
Regulation of pro-inflammatory and pro-fibrotic factors 19tively, this data suggests that CTGF rapidly signals through
TrkA activation and then through TGF-β protein dependent
processes in H9c2 cells.
Effect of TrkA on CTGF regulated fibrosis
and inflammation
The ability of k252a to regulate other effects induced by
rhCTGF was examined. As shown in Table 4, FN, Col-I and
Col-III induction by CTGF treatment was found to be
blocked by k252a. Similar profiles of results were obtained
f o rT I M P - 1a n dT I M P - 2,w h i l eP A I - 1s h o w e dv e r ys t r o n g
inhibitory effects with k252a treatment with or without
rhCTGF. For the pro- inflammatory cytokine gene expres-
sion studied, as shown in Fig. 4, two differential profiles
were observed: MCP-1 and IL-8 showed the same trends as
for the fibrotic markers (Fig. 4a–b ); in contrast, for TNF-α
and IL-6 the k252a reagent added alone showed an increased
trend compared with control, and ∼ additive effects with
CTGF and k252a combined compared with CTGF addition
alone (Fig. 4c–d). This data for TNF-α and IL-6 suggests
that TrkA activity has a tonic inhibitory effect on steady state
Table 4 Effects of blocking TrkA signaling on CTGF regulated fibrotic gene expression in H9c2 cardiomyocytes
mRNA species detected Cell Treatments
CTGF TrkA blocker (k252a) CTGF+TrkA blocker (k252a)
500ng/ml 100 nM 200 nM 100 nM 200 nM
ECM formation genes FN 161±15.5* 107±11.5 80±7.1* 144±39.7 87±9.6#
Col I 141±3.5* 80±6.3* 71±12.9* 71±15.8# 88±8.8#
Col III 139±10.7 71±5.5** 54±3.0** 65±2.1# 70±6.0##
ECM remodeling genes PAI-1 177±16.1* 30±4.1*** 12±2.7*** 28±16.7## 16±1.8###
TIMP-1 143±8.3* 80±3.2** 74±24.3* 76±6.8# 70±1.4##
TIMP-2 148±11.4* 122±13.0 86±10.9 106±10.3 116±2.4#
Data is expressed as % of control (at 100%). * P<0.05, **P<0.01, ***P<0.001 vs control; #P<0.05, ##P<0.01, ###P<0.001 vs CTGF treatment
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Fig. 4 Differential effects of
TrkA on CTGF regulation of
inflammatory gene expression.
H9c2 cells were pretreated for
1 hr with K252a at 100 nM and
200 nM and then conditioned
media with no treatment or
CTGF (500 ng/ml) was added.
The RNA was isolated at 24 h
and mRNA levls of respective
species was determine by RT-
qPCR A, MCP-1 B, IL-8 C,
TNF-α and D IL-6 mRNA. Data
is mean±SD. *, P<0.05, vs
control respectively.
#P<0.05,
##P<0.01, vs. CTGF treatment
20 X. Wang et al.TNF-α and IL-6 and that upregulatory effects of rhCTGF on
TNF-α and IL-6 (Fig. 1c) are not TrkA mediated and they
persist when TrkA activity is blocked.
Nerve growth factor up-regulates MCP-1 and IL-8
but not TNF-α or IL-6
As TrkA is a receptor for nerve growth factor (NGF)
(Wahab et al. 2005), to further examine gene expression
regulation through TrkA, 10 ng/ml and 100 ng/ml of NGF
were applied to cells and change in CTGF and inflamma-
tory cytokines gene expression was measured. NGF at
100 ng/ml up-regulated CTGF mRNA (Fig. 5a); while
MCP-1 and IL-8 (Fig. 5b and c) were increased at 10 ng/ml
by NGF treatment. No change was observed for TNF-α and
IL-6 (Fig. 4d and e). This data is consistent with the TrkA
activity blocker k252a treatment showing that observed
CTGF up-regulatory effects on TNF-α and IL-6 (Fig. 1c)
are TrkA independent (Fig. 1d).
Discussion
This study demonstrates that CTGF induces pro-fibrosis
and pro-inflammation gene expression in cultured cardiac
myocytes. CTGF gene expression is TrkA and TGF-β
dependent. CTGF effects on fibrosis and inflammatory
markers was found to consistently be TGF-β dependent.
However for the TrkA pathway in our study, while CTGF
effects on fibrotic gene expression was TrkA dependent a
differential pattern was found for the pro-inflammatory
genes. MCP-1 and IL-8 mRNA were up-regulated by
rhCTGF through TrkA signalling, but TNF-α and IL-6
mRNA species induced by rhCTGF were not through TrkA
signalling. The ability of the k252a blocker alone to
potently induce TNF-α and IL-6 mRNA implicates a basal
inhibitory effect of TrkA signalling on TNF-α and IL-6
mRNA. As TrkA signalling appears to inhibit TNF-α and
IL-6 mRNA it is then not surprising that the observed
rhCTGF induction of these two genes was not found to be
TrkA signalling dependent.
CTGF as a down stream mediator of TGF-β has been
extensively studied, including in diabetes in renal pathol-
ogy. CTGF up-regulation was reported including in diabetic
animal heart (Way et al. 2002) and by stimuli such as
aldosterone (Lee et al. 2004), and endothelin-1 (Kemp et al.
2004). in cardiomyocytes. Some studies also showed CTGF
is involved in fibrosis induction in cardiomyoctes (Dean et
al. 2005; Yun et al. 2007; Matsui and Sadoshima 2004), but
how CTGF regulates fibrotic processes in cardiomyocytes
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Fig. 5 Gene expression of CTGF and inflammatory cytokines by
nerve growth factor treatment. H9c2 Cells were treated with nerve
growth factor (NGF) 10 ng/ml and 100 ng/ml for 24 h and mRNA
levels of CTGF (a), MCP-1 (b), IL-8 (c), TNF-α (d) and IL-6 (e) were
measured by RT-qPCR and compared to control at 100%. Data is
mean±SD. * P<0.05 shows the difference of each treatment vs control
for the respective mRNA species
Regulation of pro-inflammatory and pro-fibrotic factors 21is unclear. In this study, we examined two potential
pathways describing CTGF regulation of pro-fibrotic and
pro-inflammatory gene expression. The current data is the
first work in cardiomyocytes to implicate both TGF-β and
TrkA pathways in these CTGF regulated processes and the
first to show that CTGF induces a profile of pro-
inflammatory genes in cardiomycoytes. CTGF has been
shown to induce MCP-1 and IL-6 in some cells (Sánchez-
López et al. 2009) but not in others (Qi et al. 2006),
reflecting the cell type dependence of the findings.
Like TGF-β1 mRNA and TGF-β protein, CTGF mRNA
is known to be induced in a ‘feed forward’ process by
soluble CTGF protein treatment (McLennan et al. 2004).
The current work shows that this auto-induction effect in
H9c2 cells is TGF-β and TrkA dependent. The induction of
CTGF mRNA and then endogenous CTGF protein would
be predicted to amplify the cellular responses seen for
CTGF protein addition although this was not explored in
the current work. It is notable in our studies that CTGF
protein rapidly induced phosphorylation of TrkA, and that
CTGF mRNA increase was TrkA dependent. In contrast,
TNF-α and IL-6 mRNA increases by rhCTGF protein
occurred in the absence of TrkA signalling and in the
absence of CTGF mRNA induction by rhCTGF. Thus
rhCTGF protein inducing effects on TNF-α and IL-6
mRNA is both TrkA and CTGFmRNA independent in
H9c2 cardiomyocytes. The NGF treatment data also
suggest that TrkA activation does not upregulate TNF-α
and IL-6 mRNA, although interpretation of the NGF effect
is complicated by the potential presence of a low affinity
binding NGF receptor, p75NTR, in heart cells (Zhou et al.
2004), in addition to TrkA (Wang et al. 2009), which may
also be contributing to the bimodal NGF effect seen in
Fig. 5 on MCP-1 and IL-8 induction.
The current data as shown in Fig. 3 suggests that
rhCTGF may signal sequentially through TrkA and then
TGF-β pathways. To confirm this finding detailed time
course studies of TGF-β pathway regulation would be
required, which is beyond the scope of the current work.
Thus while we found that rhCTGF rapidly induces TrkA
phosphorylation in H9c2 cells, others have shown in other
mesenchymal cell types that CTGF rapidly activates TGF-β
pathway signalling (Abreu et al. 2002).
That TrkA has differential effects in regulating CTGF
induction of pro-inflammatory cytokines could have rele-
vance to cell and tissue pathology. Thus TrkA may be
necessary for effects of CTGF such as macrophage chemo-
attraction (MCP-1) and cellular hypertrophy (IL-6), but not
for neutrophil chemotaxis (IL-8 dependent) or caspase
8 dependent apoptosis (TNF-α mediated).
In summary, the main novel finding in this work is that
in H9c2 cardiomyocytes, CTGF mediates pro-fibrosis gene
expression via both TrkA and TGF-β signalling, while
induction of pro-inflammatory cytokines by CTGF is
through TGF-β in each case. For TrkA, CTGF effects on
proinflammatory cytokines are differentially regulated. The
significance of these findings including the differential
regulation of CTGF effects can now be explored in cardiac
pathologies and in more depth at the level of differentially
regulated genes.
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